3rd Annual Tennessee Oncology Pharmacists Association Meeting

September 29th, 2018
Belmont University, Nashville, TN

Target Audience: Pharmacists

Registration Fees:
Belmont Full Time Faculty/Student: $20
Early Registration (TOPA member, through August 20): $100
Early Registration (non-member, through August 20): $125
Registration (August 21-September 14): $150
NPs, PAs, Nurses- $30
Residents- $0

Program Agenda

- 8:15am-9:15am - What’s New and Novel with Nuclides and Neuroendocrine Neoplasms? (0.1 CEUs)
  UAN: 0863-0000-18-081-L01-P
  o Jonathan Aston, PharmD, BCOP
  o Objectives
    ▪ Recognize the role of current anticancer therapies in the management of gastrointestinal neuroendocrine tumors
    ▪ Explain treatment strategies for symptom management in patients with carcinoid syndrome
    ▪ Discuss the evolving use of theranostics within gastrointestinal neuroendocrine tumors
    ▪ Describe the complexities and intricacies involved with lutetium-177 dotatate therapy

- 9:15am-9:45am - Role of the Pharmacist in Outpatient Autologous Stem Cell Transplant (0.05 CEUs)
  UAN: 0863-0000-18-082-L01-P
  o LeAnne Kennedy, PharmD, BCOP, FHOPA
  o Objectives
    ▪ Discuss the daily roles of the pharmacist with outpatient autologous stem cell transplant
    ▪ Review the potential cost savings associated with outpatient autologous stem cell transplant

- 10:00am-11:00am - Updates in Prostate Cancer (0.1 CEUs)
  UAN: 0863-0000-18-083-L01-P
  o Heather Nelkin, PharmD, BCOP
  o Objectives
    ▪ Briefly review the pathophysiology of metastatic prostate cancer
    ▪ Discuss pharmacotherapy options for treatment of metastatic prostate cancer
    ▪ Review new literature in the treatment of metastatic prostate cancer
    ▪ Evaluate a patient case related to the management of metastatic prostate cancer

- 11:00am-11:30am - The Cost of Cancer and the Role of the Oncology Pharmacist (0.05 CEUs)
Kendall Shultes, PharmD

Objectives

- Describe the benefits and barriers of utilizing a dose-rounding policy for chemotherapy/biotherapy
- Discuss payments options for high-cost drugs and their implication on the role of the oncology pharmacist

- 11:30am-12:00pm - Ongoing Payment Models and Reimbursement Systems for Oncology Infusion Medications (0.05 CEUs)
  UAN: 0863-0000-18-085-L01-P
  - Alexander Quesenberry, PharmD, BCOP, BCPS
  - Objectives
    - Discuss the CMS reimbursement cuts to 340b reimbursement outpatient claims
    - Calculate projected reimbursements from outpatient claims
    - Discuss reimbursement of newly approved medications, biosimilar and pass through status medications
    - Determine medication procurement strategy and sourcing (white, brown, clear, grey bagging)

- 1:00pm-1:30pm - Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation: New Strategies and Novel Pathways (0.05 CEUs)
  UAN: 0863-0000-18-086-L01-P
  - David Eplin, PharmD, BCOP
  - Objectives
    - Describe the prophylactic and pre-emptive treatment strategies for CMV reactivation in HSCT, including current recommendations for standard treatment guidelines
    - Recall different pharmacologic agents with anti-CMV activity, including the recently FDA-approved letermovir, such as: dosing, route, frequency, adverse effects, and other pertinent warnings
    - Review and analyze the published literature regarding letermovir in primary prophylaxis against CMV reactivation in seropositive allogeneic stem cell transplant patients
    - Evaluate letermovir’s current role and future areas for research in the treatment and prophylactic modalities for CMV reactivation in this patient population

- 1:30pm-2:30pm - An Update on Treatment of Metastatic Renal Cell Carcinoma (mRCC) (0.1 CEUs)
  UAN: 0863-0000-18-087-L01-P
  - Renee McAlister, PharmD, BCOP
  - Objectives
    - Review the pathophysiology of mRCC
    - Explore new first-line treatment options for mRCC
    - Discuss future directions for treatment of mRCC

- 2:45pm-3:15pm - Creating and Maintaining Ambulatory Student Rotations (0.05 CEUs)
  UAN: 0863-0000-18-088-L01-P
  - Bridgette Schroader, PharmD, BCOP
  - Objectives
    - Present a single center’s embedded student ambulatory model
    - Discuss the identification of appropriate student level activities
- Describe the obstacles associated with student rotations in ambulatory settings and specifically in oncology patient clinics

- 3:15pm-3:45pm - Tumor Agnostic Therapies and Clinical Trial Design (0.05 CEUs)
  UAN: 0863-0000-18-089-L01-P
  o Megan Pollack, PharmD, BCOP, BCPS
  o Objectives
    ▪ Identify the FDA-approved tumor agnostic therapies and potential tumor agnostic therapies in the drug development pipeline
    ▪ Recognize the barriers for development of tumor agnostic therapies
    ▪ Discuss clinical trial design as it pertains to tumor agnostic therapies and how these trials differ from typical clinical trial designs in oncology

- 3:45pm-4:15pm - Ruxolitinib: JAK of all trades (0.05 CEUs)
  UAN: 0863-0000-18-090-L01-P
  o Deni Trone, PharmD
  o Objectives
    ▪ Explain the mechanism of action of ruxolitinib
    ▪ Discuss indications for ruxolitinib
    ▪ Evaluate the literature supporting ruxolitinib use in various indications
    ▪ Formulate a conclusion for ruxolitinib’s place in practice

- 4:15pm-4:45pm - Collaborative Pharmacy Practice Agreement: the road to becoming a provider (0.05 CEUs)
  UAN: 0863-0000-18-091-L01-P
  o Scott Thompson, RPh
  o Objectives
    ▪ Describe a Collaborative Pharmacy Practice Agreement
    ▪ Understand the need and benefits of an agreement
    ▪ Highlight Tennessee legislature that allows for CPPAs
    ▪ Discuss the process of putting an agreement into practice

- 4:45-5:45 - New Drug Updates (0.1 CEUs)
  UAN: 0863-0000-18-092-L01-P
  o Mona Benrashid, PharmD, BCOP
  o Objectives
    ▪ Identify notable drug approvals over the last year
    ▪ Discuss mechanisms of action
    ▪ Summarize pertinent clinical studies
    ▪ Review indications, doses, adverse events, drug interactions and pertinent patient counseling points
    ▪ Highlight clinical impact and potential role in therapy

Thank you to our exhibitors Abbvie, Amgen, BMS, Eisai, Jazz, Lilly, Merck.